Literature DB >> 15900290

Linezolid and rifampin: Drug interaction contrary to expectations?

Hannes Egle, Rainer Trittler, Klaus Kümmerer, Sebastian W Lemmen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15900290     DOI： 10.1016/j.clpt.2005.01.020

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  19 in total

1.  Linezolid underexposure in a patient co-treated with venlafaxine.

Authors:  Piergiorgio Cojutti; Massimo Crapis; Matteo Bassetti; William Hope; Federico Pea
Journal:  Eur J Clin Pharmacol       Date:  2015-08-08       Impact factor: 2.953

2.  Treatment with linezolid or vancomycin in combination with rifampin is effective in an animal model of methicillin-resistant Staphylococcus aureus foreign body osteomyelitis.

Authors:  Paschalis Vergidis; Mark S Rouse; Gorane Euba; Melissa J Karau; Suzannah M Schmidt; Jayawant N Mandrekar; James M Steckelberg; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2010-12-28       Impact factor: 5.191

3.  Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis.

Authors:  Cornelia Buerger; Nele Plock; Pejman Dehghanyar; Christian Joukhadar; Charlotte Kloft
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

4.  Systematic Therapeutic Drug Monitoring for Linezolid: Variability and Clinical Impact.

Authors:  Alicia Galar; Maricela Valerio; Patricia Muñoz; Luis Alcalá; Xandra García-González; Almudena Burillo; María Sanjurjo; Santiago Grau; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

5.  Prolonged inductive effect of rifampicin on linezolid exposure.

Authors:  Cristina Gervasoni; Francesco R Simonetti; Chiara Resnati; Nitin Charbe; Emilio Clementi; Dario Cattaneo
Journal:  Eur J Clin Pharmacol       Date:  2015-03-18       Impact factor: 2.953

Review 6.  Pharmacological issues of linezolid: an updated critical review.

Authors:  Antonello Di Paolo; Paolo Malacarne; Emanuele Guidotti; Romano Danesi; Mario Del Tacca
Journal:  Clin Pharmacokinet       Date:  2010-07       Impact factor: 6.447

7.  Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis.

Authors:  Federico Pea; Mario Furlanut; Piergiorgio Cojutti; Francesco Cristini; Eleonora Zamparini; Loretta Franceschi; Pierluigi Viale
Journal:  Antimicrob Agents Chemother       Date:  2010-08-23       Impact factor: 5.191

8.  Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients.

Authors:  Tomohiro Sasaki; Hiroshi Takane; Katsuhiro Ogawa; Sayaka Isagawa; Takeshi Hirota; Shun Higuchi; Toshinobu Horii; Kenji Otsubo; Ichiro Ieiri
Journal:  Antimicrob Agents Chemother       Date:  2011-02-28       Impact factor: 5.191

9.  Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolid.

Authors:  Alex Soriano; Mar Ortega; Sebastián García; Georgina Peñarroja; Albert Bové; Miguel Marcos; Juan C Martínez; José A Martínez; Josep Mensa
Journal:  Antimicrob Agents Chemother       Date:  2007-04-30       Impact factor: 5.191

Review 10.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.